vs
Side-by-side financial comparison of CAPRICOR THERAPEUTICS, INC. (CAPR) and Globavend Holdings Ltd (GVH). Click either name above to swap in a different company.
Globavend Holdings Ltd is the larger business by last-quarter revenue ($13.7M vs $11.1M, roughly 1.2× CAPRICOR THERAPEUTICS, INC.). Globavend Holdings Ltd runs the higher net margin — 3.3% vs -63.9%, a 67.2% gap on every dollar of revenue. On growth, Globavend Holdings Ltd posted the faster year-over-year revenue change (63.7% vs -7.9%). Globavend Holdings Ltd produced more free cash flow last quarter ($-1.2M vs $-15.3M).
Capricor Therapeutics is a clinical-stage biotechnology company focused on discovering, developing and commercializing innovative biological therapies including cell and gene therapies for rare diseases, cardiovascular disorders and muscular conditions. It primarily operates in the U.S. market, addressing unmet medical needs for patient groups with limited treatment options.
Globavend Holdings Ltd is a provider of smart unattended retail solutions, focusing on the design, supply, and operation of intelligent vending machines. It primarily serves markets across Australia, New Zealand, and Southeast Asia, offering end-to-end services including hardware manufacturing, inventory management software, and after-sales support to clients in retail, FMCG, and workplace service segments.
CAPR vs GVH — Head-to-Head
Income Statement — Q4 FY2024 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.1M | $13.7M |
| Net Profit | $-7.1M | $450.3K |
| Gross Margin | — | 10.5% |
| Operating Margin | -69.1% | 5.8% |
| Net Margin | -63.9% | 3.3% |
| Revenue YoY | -7.9% | 63.7% |
| Net Profit YoY | -833.8% | -49.9% |
| EPS (diluted) | $-0.11 | $6.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 25 | — | $13.7M | ||
| Q4 24 | $11.1M | — | ||
| Q3 24 | $2.3M | — | ||
| Q2 24 | $4.0M | — | ||
| Q1 24 | $4.9M | $8.4M | ||
| Q4 23 | $12.1M | — | ||
| Q3 23 | $6.2M | — | ||
| Q2 23 | $3.9M | — |
| Q1 25 | — | $450.3K | ||
| Q4 24 | $-7.1M | — | ||
| Q3 24 | $-12.6M | — | ||
| Q2 24 | $-11.0M | — | ||
| Q1 24 | $-9.8M | $898.8K | ||
| Q4 23 | $-762.1K | — | ||
| Q3 23 | $-6.4M | — | ||
| Q2 23 | $-7.4M | — |
| Q1 25 | — | 10.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 19.8% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q1 25 | — | 5.8% | ||
| Q4 24 | -69.1% | — | ||
| Q3 24 | -575.2% | — | ||
| Q2 24 | -291.9% | — | ||
| Q1 24 | -209.2% | 13.8% | ||
| Q4 23 | -10.6% | — | ||
| Q3 23 | -111.0% | — | ||
| Q2 23 | -197.8% | — |
| Q1 25 | — | 3.3% | ||
| Q4 24 | -63.9% | — | ||
| Q3 24 | -555.2% | — | ||
| Q2 24 | -277.0% | — | ||
| Q1 24 | -199.6% | 10.7% | ||
| Q4 23 | -6.3% | — | ||
| Q3 23 | -103.3% | — | ||
| Q2 23 | -188.0% | — |
| Q1 25 | — | $6.01 | ||
| Q4 24 | $-0.11 | — | ||
| Q3 24 | $-0.38 | — | ||
| Q2 24 | $-0.35 | — | ||
| Q1 24 | $-0.31 | $12.57 | ||
| Q4 23 | $0.02 | — | ||
| Q3 23 | $-0.25 | — | ||
| Q2 23 | $-0.29 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $151.5M | $915.2K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $145.5M | $5.7M |
| Total Assets | $170.5M | $6.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | — | $915.2K | ||
| Q4 24 | $151.5M | — | ||
| Q3 24 | $85.0M | — | ||
| Q2 24 | $29.5M | — | ||
| Q1 24 | $39.9M | $2.5M | ||
| Q4 23 | $39.5M | — | ||
| Q3 23 | $28.5M | — | ||
| Q2 23 | $37.8M | — |
| Q1 25 | — | $5.7M | ||
| Q4 24 | $145.5M | — | ||
| Q3 24 | $68.3M | — | ||
| Q2 24 | $11.5M | — | ||
| Q1 24 | $18.4M | $4.4M | ||
| Q4 23 | $22.6M | — | ||
| Q3 23 | $-1.8M | — | ||
| Q2 23 | $2.7M | — |
| Q1 25 | — | $6.4M | ||
| Q4 24 | $170.5M | — | ||
| Q3 24 | $93.0M | — | ||
| Q2 24 | $38.3M | — | ||
| Q1 24 | $49.4M | $6.0M | ||
| Q4 23 | $58.7M | — | ||
| Q3 23 | $37.2M | — | ||
| Q2 23 | $46.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.8M | $-906.3K |
| Free Cash FlowOCF − Capex | $-15.3M | $-1.2M |
| FCF MarginFCF / Revenue | -137.3% | -8.8% |
| Capex IntensityCapex / Revenue | 4.4% | 2.2% |
| Cash ConversionOCF / Net Profit | — | -2.01× |
| TTM Free Cash FlowTrailing 4 quarters | $-41.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | — | $-906.3K | ||
| Q4 24 | $-14.8M | — | ||
| Q3 24 | $-11.6M | — | ||
| Q2 24 | $-12.3M | — | ||
| Q1 24 | $-1.3M | $-256.6K | ||
| Q4 23 | $-11.6M | — | ||
| Q3 23 | $-8.8M | — | ||
| Q2 23 | $-9.4M | — |
| Q1 25 | — | $-1.2M | ||
| Q4 24 | $-15.3M | — | ||
| Q3 24 | $-11.7M | — | ||
| Q2 24 | $-12.3M | — | ||
| Q1 24 | $-1.9M | $-730.0K | ||
| Q4 23 | $-12.2M | — | ||
| Q3 23 | $-9.1M | — | ||
| Q2 23 | $-9.6M | — |
| Q1 25 | — | -8.8% | ||
| Q4 24 | -137.3% | — | ||
| Q3 24 | -515.2% | — | ||
| Q2 24 | -310.9% | — | ||
| Q1 24 | -38.3% | -8.7% | ||
| Q4 23 | -100.5% | — | ||
| Q3 23 | -146.5% | — | ||
| Q2 23 | -243.9% | — |
| Q1 25 | — | 2.2% | ||
| Q4 24 | 4.4% | — | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 12.4% | 5.6% | ||
| Q4 23 | 4.6% | — | ||
| Q3 23 | 4.4% | — | ||
| Q2 23 | 3.5% | — |
| Q1 25 | — | -2.01× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.29× | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
